IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences (NASDAQ: IDYA) announced the granting of inducement stock options to a new employee. The Compensation Committee approved non-qualified stock options to purchase 31,400 shares of common stock under the company's 2023 Employment Inducement Incentive Award Plan.
The stock options were granted at an exercise price of $25.69 per share, matching IDEAYA's closing price on the grant date. The options have a 10-year term and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years, subject to continued employment.
IDEAYA Biosciences (NASDAQ: IDYA) ha annunciato l'assegnazione di stock options di induzione a un nuovo dipendente. Il Compensation Committee ha approvato stock option non qualificati per l'acquisto di 31.400 azioni ordinarie ai sensi del piano aziendale 2023 di Incentivi di Induzione all'Assunzione.
Le stock option sono state assegnate con un prezzo di esercizio di $25,69 per azione, in corrispondenza al prezzo di chiusura di IDEAYA nel giorno della concessione. Le opzioni hanno una durata di 10 anni e matureranno in quattro anni, con il 25% che matura dopo il primo anno e il restante 75% maturerà mensilmente nei successivi tre anni, soggetto a continuo rapporto di lavoro.
IDEAYA Biosciences (NASDAQ: IDYA) anunció la concesión de opciones de compra por inducción a un nuevo empleado. El Comité de Compensación aprobó opciones de acciones no cualificadas para comprar 31.400 acciones de acciones ordinarias bajo el plan de Premio por Inducción de Empleo 2023 de la empresa.
Las opciones se concedieron a un precio de ejercicio de $25,69 por acción, que iguala el precio de cierre de IDEAYA en la fecha de la concesión. Las opciones tienen un plazo de 10 años y se consolidarán durante cuatro años, con un 25% adquirido tras el primer año y el 75% restante adquirido mensualmente durante los tres años siguientes, sujeto a la continuidad en el empleo.
IDEAYA Biosciences (NASDAQ: IDYA)가 신규 직원에게 inducement 주식 옵션을 부여했다고 발표했습니다. 보상위원회는 회사의 2023년 채용 유도 보상 계획에 따라 31,400주의 보통주를 매수할 수 있는 비자격 주식 옵션을 승인했습니다.
옵션의 행사가격은 $25.69/주로 부여일의 IDEAYA 종가와 일치합니다. 이 옵션은 10년의 기간을 가지며 4년 동안 vest가 진행되며, 1년 차에 25%가 vest되고 나머지 75%는 이후 3년 동안 매월 vest됩니다. 이는 지속적인 고용에 따라 달라집니다.
IDEAYA Biosciences (NASDAQ : IDYA) a annoncé l'octroi d'options d'achat incitatives à un nouvel employé. Le Comité de rémunération a approuvé des options d'achat d'actions non qualifiées permettant d'acheter 31 400 actions ordinaires dans le cadre du plan 2023 d'induction à l'embauche de l'entreprise.
Les options ont été octroyées à un prix d'exercice de 25,69 $ par action, égal au cours de clôture d'IDEAYA à la date d'attribution. Les options ont une durée de 10 ans et seront acquises sur une période de quatre ans, avec 25 % acquises après la première année et les 75 % restants acquises mensuellement au cours des trois années suivantes, sous réserve du maintien de l'emploi.
IDEAYA Biosciences (NASDAQ: IDYA) gab die Vergabe von Inducement-Aktienoptionen an einen neuen Mitarbeiter bekannt. Der Vergütungsausschuss genehmigte nicht qualifizierte Aktienoptionen zum Erwerb von 31.400 Aktien Stammaktien gemäß dem 2023 Employment Inducement Incentive Award Plan des Unternehmens.
Die Optionen wurden zu einem Ausübungspreis von $25,69 pro Aktie vergeben, der dem Schlusskurs von IDEAYA am Ausgabedatum entspricht. Die Optionen haben eine Laufzeit von 10 Jahren und vesten über vier Jahre, wobei 25% nach dem ersten Jahr vesten und die verbleibenden 75% monatlich über die folgenden drei Jahre vesten, vorbehaltlich einer fortlaufenden Anstellung.
IDEAYA Biosciences (ناسداك: IDYA) أعلنت عن منح خيارات أسهم تحفيزية لموظف جديد. وافقت لجنة التعويض على خيارات أسهم غير مؤهلة لشراء 31,400 سهماً من الأسهم العادية بموجب خطة جائزة التحفيز التوظيفي 2023 للشركة.
تم منح الخيارات بسعر تنفيذ قدره $25.69 للسهم، وهو يساوي سعر إغلاق IDEAYA في تاريخ المنحة. تتمتع الخيارات بفترة صلاحية 10 سنوات وسيتم vesting على مدى أربع سنوات، مع استحقاق 25% بعد السنة الأولى و75% المتبقية vesting شهرياً خلال السنوات الثلاث التالية، رهناً باستمرار التوظيف.
- None.
- None.
The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302567785.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
What stock options did IDEAYA Biosciences (IDYA) grant to its new employee?
What is the vesting schedule for IDEAYA's (IDYA) new employee stock options?
What is the purpose of IDEAYA's (IDYA) 2023 Inducement Plan?
How long is the term of IDEAYA's (IDYA) newly granted stock options?
